GlassScriptPhysician profile
James Robert Wharton
NPI 1386619203
$1,160,677.29
in general payments reported to CMS, 2019-2025
37 companies · $65K in 2025
The $65K reported for 2025 was more than what 97% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $205K · 2020: $200K · 2021: $206K · 2022: $201K · 2023: $163K · 2024: $121K · 2025: $65K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $239K · Travel and Lodging: $55K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $41K · Food and Beverage: $12K · Consulting Fee: $2,800 · Education: $549.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $238,629.00 |
| Travel and Lodging | $54,843.46 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $40,500.00 |
| Food and Beverage | $11,554.59 |
| Consulting Fee | $2,800.00 |
| Education | $549.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $866,140.18 | 2019-2025 | Ilumya, Blu-U, Odomzo |
| Amgen INC. | $214,947.04 | 2019-2025 | Otezla, Otezla |
| Celgene Corporation | $42,086.91 | 2019 | |
| Incyte Corporation | $27,253.99 | 2020-2024 | Opzelura |
| Abbvie INC. | $2,856.54 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $1,098.30 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Almirall LLC | $1,015.18 | 2021-2025 | Klisyri, Seysara |
| Ucb, INC. | $998.20 | 2019-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $685.91 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $571.63 | 2022-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $535.83 | 2019-2025 | |
| Pfizer INC. | $256.49 | 2019-2025 | |
| Genzyme Corporation | $255.28 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $233.79 | 2021-2025 | Dupixent, Libtayo |
| Organogenesis INC. | $189.98 | 2019-2024 | Puraply |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $179.98 | 2024-2025 | |
| Stemline Therapeutics INC. | $144.46 | 2020-2021 | |
| Dermavant Sciences, INC. | $144.12 | 2023-2024 | Vtama |
| Leo Pharma INC. | $138.61 | 2019-2025 | Adbry, Anzupgo |
| Biofrontera INC. | $132.37 | 2019-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Galderma Laboratories, L.P. | $124.45 | 2019-2025 | Nemluvio |
| Arcutis Biotherapeutics, INC. | $119.74 | 2023-2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $97.77 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.13 | 2024 | Spevigo |
| Organon LLC | $63.70 | 2024-2025 | Vtama |
| Dermira, INC. | $59.65 | 2020-2021 | |
| Botanix Sb INC | $40.73 | 2025 | Sofdra |
| Allergan, INC. | $39.69 | 2019 | |
| Surgenex LLC | $38.43 | 2025 | Ardeograft, Pellograft, Surmatrix |
| Journey Medical Corporation | $31.36 | 2025 | |
| Verrica Pharmaceuticals INC. | $26.69 | 2025 | Ycanth |
| Bausch Health US, LLC | $22.72 | 2021 | |
| Mindera Corp | $21.42 | 2025 | |
| Genentech USA, INC. | $19.63 | 2022 | |
| Hill Dermaceuticals, INC. | $14.63 | 2025 | Tolak |
| Sensus Healthcare, INC. | $13.97 | 2020 | |
| Medtronic Vascular, INC. | $13.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Wharton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.